# EDGAR Filing Document

**Accession Number:** 0001177523
**File Stem:** 0001213900-26-001456
**Filing Date:** 2026-1
**Character Count:** 12972
**Document Hash:** f78694f1045b98524b4195044a7ab1a5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-001456.hdr.sgml**: 20260105

**ACCESSION NUMBER**: 0001213900-26-001456

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260105

**DATE AS OF CHANGE**: 20260105

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Zentalis Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001725160
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 823607803
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91478
- **FILM NUMBER:** 26509092

**BUSINESS ADDRESS:**
- **STREET 1:** 10275 SCIENCE CENTER DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 263-4333

**MAIL ADDRESS:**
- **STREET 1:** 10275 SCIENCE CENTER DRIVE
- **STREET 2:** SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zentalis Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20200107

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Zeno Pharma, LLC
- **DATE OF NAME CHANGE:** 20171212
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** WALTERS GROUP
- **CENTRAL INDEX KEY:** 0001177523

**ORGANIZATION NAME:**
- **EIN:** 880235477
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G/A

**BUSINESS ADDRESS:**
- **STREET 1:** 8975 S. PECOS RD. UNIT #6A
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89074
- **BUSINESS PHONE:** 760-419-8408

**MAIL ADDRESS:**
- **STREET 1:** 8975 S. PECOS RD. UNIT #6A
- **CITY:** HENDERSON
- **STATE:** NV
- **ZIP:** 89074

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**Issuer:** Zentalis Pharmaceuticals, Inc.

**Title of Class of Securities:** Common Stock, $0.001 par value per share

**CUSIP Number:** 98943L107

**Date of Event Which Requires Filing of this Statement:** 12/31/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [x] Rule 13d-1(c)

- [ ] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Walters William T | Names of Reporting Persons<br>Walters William T |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>13509973.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>13509973.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>13509973.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>13509973.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>19.7% | Percent of Class Represented by Amount in Row (9)<br>19.7% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

---

| 1. | Names of Reporting Persons<br>WALTERS GROUP | Names of Reporting Persons<br>WALTERS GROUP |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>NV | Citizenship or Place of Organization<br>NV |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>13509973.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>13509973.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>13509973.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>13509973.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>19.7% | Percent of Class Represented by Amount in Row (9)<br>19.7% |
| 12. | Type of Reporting Person (See Instructions)<br>PN | Type of Reporting Person (See Instructions)<br>PN |

**Comment for Type of Reporting Person:** General partnership

---

| 1. | Names of Reporting Persons<br>Walters, Susan B. | Names of Reporting Persons<br>Walters, Susan B. |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>X1 | Citizenship or Place of Organization<br>X1 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>13509973.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>13509973.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>13509973.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>13509973.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>19.7% | Percent of Class Represented by Amount in Row (9)<br>19.7% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

---

**Item 1(a). Name of Issuer:**
Zentalis Pharmaceuticals, Inc.

**Item 1(b). Address of Issuer's Principal Executive Offices:**
10275 SCIENCE CENTER DRIVE, SAN DIEGO, CALIFORNIA, 92121.

**Item 2(a). Name of Person Filing:**
This Schedule 13G ("Schedule") is being filed by William T. Walters, The Walters Group (the "TWG") and Susan B. Walters (together, the "Reporting Persons"). TWG directly owns the shares of common stock reported in this Schedule (the "Shares"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims beneficial ownership with respect to any Shares other than the Shares owned directly by such Reporting Person (if any).

**Item 2(b). Address of Principal Business Office:**
The address of each Reporting Person is 8975 S. Pecos Road, Unit 6A, Henderson, Nevada 89074.

**Item 2(c). Citizenship:**
TWG was organized as a Nevada general partnership. William T. Walters and Susan B. Walters are U.S. citizens.

**Item 2(d). Title of Class of Securities:**
Common Stock, $0.001 par value per share

**Item 2(e). CUSIP Number:**
98943L107

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

Each of William T. Walters, TWG and Susan B. Walters may be deemed to beneficially own 13,509,973 Shares.

**(b) Percent of class:**

Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon the sum of (i) 72,250,779 shares of common stock outstanding as of November 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 10, 2025; and (ii) 3,928,571 shares of common stock issued to certain investors pursuant to an at-the-market offering by the Issuer on December 18, 2025, as set forth on the Schedule 13G jointly filed with the SEC on December 30, 2025 by 5AM Opportunities II, L.P., 5AM Opportunities II (GP), LLC, 5AM Opportunities Master Fund L.P., 5AM Opportunities (GP), LLC, Andrew J. Schwab, Dr. Kush Parmar and Anna Yaeger; less 7,500,000 shares of common stock the Issuer repurchased from Matrix Capital Master Fund, LP on December 15, 2025, as reported on the Issuer's Current Report on Form 8-K filed with the SEC on December 15, 2025.

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

0

**(ii) Shared power to vote or to direct the vote:**

13,509,973

**(iii) Sole power to dispose or to direct the disposition of:**

0

**(iv) Shared power to dispose or to direct the disposition of:**

13,509,973

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Walters William T**

**Date:** 01/05/2026

**By:** /s/ William T. Walters

**Name & Title:** William T. Walters/Individual

**WALTERS GROUP**

**Date:** 01/05/2026

**By:** /s/ Susan B. Walters

**Name & Title:** Susan B. Walters/General Partner

**Walters, Susan B.**

**Date:** 01/05/2026

**By:** /s/ Susan B. Walters

**Name & Title:** Susan B. Walters/Individual